Executive All-Change: Bayer's Weinand To Join Sanofi, While Sanofi's Oelrich To Take His Place At Bayer
A head-spinning change of executives in Europe's leading pharmaceutical companies will see a new head of pharmaceuticals at Bayer and the former incumbent fetching up at Sanofi in the US.
You may also be interested in...
The German group has been talking up its pharmaceuticals division but analysts are not convinced it has addressed the elephant in the room that is the loss of patent protection for its blockbuster anticoagulant Xarelto in 2024.
AbbVie faces analysts just a couple weeks after Humira biosimilars hit the market, and with Gilead launching authorized generics of its hepatitis C combos, the TNF franchise is not the only one under attack at AbbVie. Investors are keen to see AstraZeneca start its turnaround to growth, while Lilly is looking to a strong future based on new diabetes data and Bayer braces for a new push in oncology.
Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.